Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics

Mallinckrodt plc Ordinary Shares (MNK)

Today's Latest Price: $4.81 USD

0.06 (-1.23%)

Updated Jan 28 10:29am

Add MNK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MNK Stock Summary

  • With a one year PEG ratio of 0.01, Mallinckrodt plc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 0.26% of US stocks.
  • Over the past twelve months, MNK has reported earnings growth of -1,473.14%, putting it ahead of just 1.18% of US stocks in our set.
  • In terms of volatility of its share price, MNK is more volatile than 98.01% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Mallinckrodt plc are PHX, RRC, NGS, EVOL, and MDR.
  • MNK's SEC filings can be seen here. And to visit Mallinckrodt plc's official web site, go to
MNK Daily Price Range
MNK 52-Week Price Range

MNK Stock Price Chart More Charts

MNK Price/Volume Stats

Current price $4.81 52-week high $27.33
Prev. close $4.87 52-week low $1.43
Day low $4.65 Volume 1,684,678
Day high $4.99 Avg. volume 9,152,210
50-day MA $3.74 Dividend yield N/A
200-day MA $6.53 Market Cap 404.49M

Mallinckrodt plc Ordinary Shares (MNK) Company Bio

Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.

MNK Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$4.81$41.54 642%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Mallinckrodt plc. To summarize, we found that Mallinckrodt plc ranked in the 87th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Mallinckrodt plc, consider:

  • 8% of the company's capital comes from equity, which is greater than only 1.87% of stocks in our cash flow based forecasting set.
  • Mallinckrodt plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -11.5. This coverage rate is greater than that of only 5.88% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 18. This value is greater than 98.02% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

TYHT, INCY, THC, STAA, and LNTH can be thought of as valuation peers to MNK, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

MNK Latest News Stream

Event/Time News Detail
Loading, please wait...

MNK Latest Social Stream

Loading social stream, please wait...

View Full MNK Social Stream

MNK Price Returns

1-mo 39.42%
3-mo 54.66%
6-mo -27.34%
1-year -77.71%
3-year -89.78%
5-year -95.58%
YTD 37.82%
2019 -77.91%
2018 -29.96%
2017 -54.72%
2016 -33.24%
2015 -24.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6521 seconds.